6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.

Animals Antiparkinson Agents / pharmacology Buspirone / pharmacology Dopamine Levodopa Oxidopamine Pars Reticulata Rats Substantia Nigra

Journal

British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536

Informations de publication

Date de publication:
09 2020
Historique:
received: 18 12 2019
revised: 08 05 2020
accepted: 11 05 2020
pubmed: 29 5 2020
medline: 22 6 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT Buspirone was studied using in vivo single-unit, electrocorticogram, local field potential recordings along with microdialysis and immunohistochemistry in naïve/sham, 6-hydroxydopamine (6-OHDA)-lesioned or 6-OHDA-lesioned and l-DOPA-treated (6-OHDA/l-DOPA) rats. Local buspirone inhibited SNr neuron activity in all groups. However, systemic buspirone reduced burst activity in 6-OHDA-lesioned rats (with or without l-DOPA treatment), whereas 8-OH-DPAT, a full 5-HT The effects of buspirone in SNr are influenced by dopamine loss and l-DOPA treatment. The present results suggest that the regulation of burst activity of the SNr induced by DA loss may be a good target to test new drugs for the treatment of PD and LID.

Sections du résumé

BACKGROUND AND PURPOSE
l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT
EXPERIMENTAL APPROACH
Buspirone was studied using in vivo single-unit, electrocorticogram, local field potential recordings along with microdialysis and immunohistochemistry in naïve/sham, 6-hydroxydopamine (6-OHDA)-lesioned or 6-OHDA-lesioned and l-DOPA-treated (6-OHDA/l-DOPA) rats.
KEY RESULTS
Local buspirone inhibited SNr neuron activity in all groups. However, systemic buspirone reduced burst activity in 6-OHDA-lesioned rats (with or without l-DOPA treatment), whereas 8-OH-DPAT, a full 5-HT
CONCLUSIONS AND IMPLICATIONS
The effects of buspirone in SNr are influenced by dopamine loss and l-DOPA treatment. The present results suggest that the regulation of burst activity of the SNr induced by DA loss may be a good target to test new drugs for the treatment of PD and LID.

Identifiants

DOI: 10.1111/bph.15145 PMID: 32464686 PMC: PMC7429490
pubmed: 32464686
doi: 10.1111/bph.15145
pmc: PMC7429490
doi:

Substances chimiques

Antiparkinson Agents 0
Levodopa 46627O600J
Oxidopamine 8HW4YBZ748
Buspirone TK65WKS8HL
Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3957-3974

Subventions

Organisme : Eusko Jaurlaritza
ID : IT747-13
Organisme : Eusko Jaurlaritza
ID : T747-13
Organisme : Ministerio de Economía y Competitividad
ID : SAF2016-77758-R

Informations de copyright

© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Références

Br J Psychiatry. 1994 Mar;164(3):372-9
pubmed: 8199791
Neurobiol Dis. 2014 Feb;62:233-40
pubmed: 24135006
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Int Rev Neurobiol. 2019;146:259-279
pubmed: 31349930
Neurochem Int. 2012 Dec;61(8):1344-56
pubmed: 23032407
Eur J Neurosci. 2000 Jan;12(1):247-56
pubmed: 10651879
Brain. 2013 Jul;136(Pt 7):2098-108
pubmed: 23757762
Neurology. 2013 May 14;80(20):1850-5
pubmed: 23596065
Neuroscience. 2009 Mar 17;159(2):850-61
pubmed: 19174182
J Neurol. 2017 Aug;264(8):1583-1607
pubmed: 28054129
Neuropharmacology. 2019 Apr;148:1-10
pubmed: 30612008
Neurobiol Dis. 2006 Jun;22(3):586-98
pubmed: 16531050
Eur J Pharmacol. 1986 Sep 23;129(1-2):123-30
pubmed: 2876903
J Clin Neurosci. 2008 May;15(5):559-67
pubmed: 18378458
Neuroscience. 1996 May;72(1):141-56
pubmed: 8730713
Br J Pharmacol. 2020 Sep;177(17):3957-3974
pubmed: 32464686
Parkinsonism Relat Disord. 2009 Jul;15(6):445-52
pubmed: 19196540
Curr Protoc Neurosci. 2007 Oct;Chapter 9:Unit 9.25
pubmed: 18428668
Br J Pharmacol. 2018 Mar;175(5):782-796
pubmed: 29232769
J Clin Invest. 2014 Mar;124(3):1340-9
pubmed: 24531549
J Neurochem. 2011 Sep;118(6):1043-55
pubmed: 21740438
PLoS One. 2008 Apr 16;3(4):e2004
pubmed: 18414674
J Neural Transm Suppl. 2006;(70):27-30
pubmed: 17017505
Ann Neurol. 2010 Nov;68(5):619-28
pubmed: 20882603
N Engl J Med. 1988 Apr 7;318(14):876-80
pubmed: 3352672
Neurochem Res. 2003 Apr;28(3-4):565-73
pubmed: 12675146
J Comp Neurol. 1987 Jun 15;260(3):435-52
pubmed: 2439552
Br J Pharmacol. 2016 Jul;173(13):2135-46
pubmed: 26805402
Neurobiol Dis. 2015 Feb;74:336-46
pubmed: 25517101
J Neurol. 2011 Nov;258(11):2048-53
pubmed: 21533825
Mov Disord. 2007 Jun 15;22(8):1150-6
pubmed: 17469208
PLoS One. 2012;7(8):e42652
pubmed: 22880070
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Exp Neurol. 2019 Dec;322:113036
pubmed: 31425688
Neuropharmacology. 2001 Jul;41(1):72-8
pubmed: 11445187
Eur J Neurosci. 2012 Sep;36(6):2839-48
pubmed: 22762478
Brain. 2015 Oct;138(Pt 10):2964-73
pubmed: 26209314
Int J Neuropsychopharmacol. 2013 Mar;16(2):445-58
pubmed: 22827916
Exp Neurol. 2016 Mar;277:35-45
pubmed: 26687972
Neuroscience. 1988 Jan;24(1):19-28
pubmed: 3368048
Neuroscience. 2009 Sep 15;162(4):1091-100
pubmed: 19410634
Prog Brain Res. 2008;172:423-63
pubmed: 18772045
Mov Disord. 2008;23 Suppl 3:S613-22
pubmed: 18781663
J Neurochem. 2007 Apr;101(2):483-97
pubmed: 17359492
Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14
pubmed: 17553556
Neurobiol Dis. 2016 May;89:88-100
pubmed: 26852950
Neuroscience. 1997 Feb;76(4):1159-71
pubmed: 9027876
Neuropharmacology. 2014 Apr;79:726-37
pubmed: 24333147
Neurophysiol Clin. 2015 Nov;45(4-5):371-88
pubmed: 26319759
Front Neural Circuits. 2014 Mar 17;8:21
pubmed: 24672433
Br J Pharmacol. 2019 Jul;176(13):2146-2161
pubmed: 30895594
Neurology. 2003 Feb 25;60(4):601-5
pubmed: 12601099
Neuropharmacology. 2009 Dec;57(7-8):725-30
pubmed: 19715708
J Neurochem. 2010 Mar;112(6):1465-76
pubmed: 20050978
Am J Med. 1986 Mar 31;80(3B):1-9
pubmed: 2870639
Neurology. 2001 Nov 27;57(10):1829-34
pubmed: 11723272
Neuropharmacology. 2013 Aug;71:273-81
pubmed: 23602989
J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250
pubmed: 29511826
J Neural Transm (Vienna). 2008 May;115(5):721-9
pubmed: 18335163
Front Cell Neurosci. 2017 Sep 12;11:274
pubmed: 28955204
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
Eur J Neurosci. 2006 Dec;24(11):3213-22
pubmed: 17156382
Neuropharmacology. 2018 Sep 1;139:61-67
pubmed: 29969592
Exp Neurol. 2018 Apr;302:155-168
pubmed: 29339052
Basal Ganglia. 2014 Apr 1;3(4):187-195
pubmed: 24729952
Behav Brain Res. 2007 Apr 16;179(1):76-89
pubmed: 17306893
Parkinsonism Relat Disord. 2019 May;62:141-147
pubmed: 30616868
Neuropharmacology. 1988 Jul;27(7):707-15
pubmed: 2901680
Neuroscience. 1996 May;72(1):89-97
pubmed: 8730708
Neuroscience. 2001;106(2):313-30
pubmed: 11566503
PLoS One. 2011;6(9):e24679
pubmed: 21931808
Neurochem Int. 2012 Dec;61(7):1160-71
pubmed: 22940695
Prog Biophys Mol Biol. 1989;53(1):1-31
pubmed: 2682781
J Pharmacol Exp Ther. 1993 Apr;265(1):7-15
pubmed: 8474032

Auteurs

Sergio Vegas-Suárez (S)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
Autonomic and Movement Disorders Unit, Neurodegenerative Diseases, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain.
ORCID: 0000-0001-5925-189X

Clarissa Anna Pisanò (CA)

Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy.
Neuroscience Center and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy.
ORCID: 0000-0001-9659-7400

Catalina Requejo (C)

LaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain.
ORCID: 0000-0002-5440-5455

Harkaitz Bengoetxea (H)

LaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain.
ORCID: 0000-0002-7805-2420

Jose Vicente Lafuente (JV)

LaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain.
ORCID: 0000-0001-7246-0987

Michele Morari (M)

Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy.
Neuroscience Center and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy.
ORCID: 0000-0002-4601-4454

Cristina Miguelez (C)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
Autonomic and Movement Disorders Unit, Neurodegenerative Diseases, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain.
ORCID: 0000-0001-6624-2932

Luisa Ugedo (L)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
Autonomic and Movement Disorders Unit, Neurodegenerative Diseases, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain.
ORCID: 0000-0001-5993-0606

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Antidyskinésiques › Antiparkinsoniens › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Composés polycycliques › Spiranes › Buspirone › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Dopamine › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Dopa › Lévodopa › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Dopamine › Hydroxydopamines › Oxidopamine › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Mésencéphale › Pédoncule cérébral › Substantia nigra › Pars reticulata › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › 6-Hydroxydopamine lesion and levodopa...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Mésencéphale › Pédoncule cérébral › Substantia nigra › 6-Hydroxydopamine lesion and levodopa...